Vistin Pharma ASAOSL: VISTN

Vistin Pharma ASA: Invitation to Q2 2026 conference call

· Issued by Vistin Pharma ASA

Summary by 6ix AI

Vistin Pharma ASA, a Norwegian maker of the diabetes drug ingredient Metformin Hydrochloride, will release its second quarter and year-to-date 2026 results on Thursday, August 20, 2026, and host a conference call for shareholders and other interested parties that day at 08:30 CET.

Key details

  • A question-and-answer session will follow the management discussion, and the call will be available by webcast and by telephone with online registration.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/vistin-pharma-asa-invitation-to-q2-2026-conference-call

Oslo, Norway, 13 August 2026

Vistin Pharma ASA (VISTN) will release its second quarter and YTD 2026 results on Thursday 20th of August 2026. Vistin Pharma will host a conference call for all shareholders and other interested parties on the same day at 08:30 CET. There will be a Q&A session following the management discussion.

The second quarter conference call will be accessible via web and audio through the following access points:

Webcast: https://edge.media-server.com/mmc/p/abe93pzc

Telephone conference (online registration):

https://register-conf.media-server.com/register/BIca3298faa94f4bbb900f07289bc40eb7

*****

For further information, please contact:

Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com

About Vistin Pharma | www.vistin.com

Vistin Pharma is a Norwegian pharmaceutical company producing Metformin Hydrochloride (API). The Metformin is also available as Direct Compressible lubricated granules. As a solely dedicated European Metformin producer, Vistin Pharma is a well-positioned supplier to leading pharmaceutical companies. Vistin Pharma is headquartered in Oslo, Norway, and has highly qualified employees and a dedicated manufacturing facility in Kragerø.

Vistin Pharma ASA on 6ix

Story so far

Earlier from Vistin Pharma

Later from Vistin Pharma

All Vistin Pharma news releases